SCOPUS 정보 검색 플랫폼

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1518-1522

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9

(6) McLeod, H L a,f Graham, M A a,b Aamdal, S c Setanoians, A a Groot, Y d Lund, B e

a UNIVERSITY OF GLASGOW (United Kingdom)

b Sanofi Winthrop Research Division (United Kingdom)

c OSLO UNIVERSITY HOSPITAL (Norway)

d Europ Org for Res and T (Netherlands)

e Rigshospitalet (Denmark)

f UNIVERSITY OF ABERDEEN (United Kingdom)

Author keywords

Bioreductive agents; Chemotherapy; EO9; Limited sampling methods; Pharmacokinetics; Phase I

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; INDOLOQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 0030217846 PISSN: 09598049 EISSN: None Source Type: Journal
DOI: 10.1016/0959-8049(96)00120-7 Document Type: Article

Times cited : (21)

References (12)

1
- 0028657069
- Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent
- 1. Verweij J, Aamdal S, Schellens J, Koier I, Lund B. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. Oncology Res 1994, 6, 519-523.
- (1994) Oncology Res , vol.6 , pp. 519-523
- Verweij, J.¹ Aamdal, S.² Schellens, J.³ Koier, I.⁴ Lund, B.⁵

2
- 0027450014
- EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
- 2. Hendriks HR, Pizao PE, Berger DP, et al. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 1993, 29A, 897-906.
- (1993) Eur J Cancer , vol.29 A , pp. 897-906
- Hendriks, H.R.¹ Pizao, P.E.² Berger, D.P.³

3
- 0026519089
- Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents
- 3. Workman P, Binger M, Kooistra KL. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys 1992, 22, 717-720.
- (1992) Int J Radiat Oncol Biol Phys , vol.22 , pp. 717-720
- Workman, P.¹ Binger, M.² Kooistra, K.L.³

4
- 0028338822
- Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9
- 4. Schellens JHM, Planting AST, van Acker BAC, et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 1994, 86, 906-912.
- (1994) J Natl Cancer Inst , vol.86 , pp. 906-912
- Schellens, J.H.M.¹ Planting, A.S.T.² Van Acker, B.A.C.³

5
- 0000729601
- Phase I study of the bioreductive indoloquinone EO9
- 5. Lund B, Aamdal S, Koier I. Phase I study of the bioreductive indoloquinone EO9. Ann Oncol 1994, S5, 136.
- (1994) Ann Oncol , vol.S5 , pp. 136
- Lund, B.¹ Aamdal, S.² Koier, I.³

6
- 0024360395
- Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
- 6. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989, 16, 327-336.
- (1989) Clin Pharmacokinet , vol.16 , pp. 327-336
- Evans, W.E.¹ Relling, M.V.²

7
- 0001473075
- Phase II studies with EO9 in breast, colorectal, gastric, pancreatic, and NSCLC
- 7. Wanders J, Pavlidis N, Gamucci T, et al. Phase II studies with EO9 in breast, colorectal, gastric, pancreatic, and NSCLC. Eur J Cancer 1995, 31A, 565.
- (1995) Eur J Cancer , vol.31 A , pp. 565
- Wanders, J.¹ Pavlidis, N.² Gamucci, T.³

8
- 0027246472
- Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine
- 8. Schellens JH, Loos WJ, Beijnen JH, et al. Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine. J Chromatogr Biomed Appl 1993, 615, 309-315.
- (1993) J Chromatogr Biomed Appl , vol.615 , pp. 309-315
- Schellens, J.H.¹ Loos, W.J.² Beijnen, J.H.³

9
- 0018387530
- A program package for simulation and parameter estimation in pharmacokinetic systems
- 9. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Prof Biomed 1979, 9, 115-134.
- (1979) Comput Prof Biomed , vol.9 , pp. 115-134
- D'Argenio, D.Z.¹ Schumitzky, A.²

10
- 0028237664
- Limited-sampling models for anticancer agents
- 10. van Warmerdam LJC, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 1994, 120, 427-433.
- (1994) J Cancer Res Clin Oncol , vol.120 , pp. 427-433
- Van Warmerdam, L.J.C.¹ Ten Bokkel Huinink, W.W.² Maes, R.A.A.³ Beijnen, J.H.⁴

11
- 0027477057
- Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients
- 11. Rodman JH, Furman WL, Sunderland M, Rivera G, Evans WE. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 1993, 11, 287-293.
- (1993) J Clin Oncol , vol.11 , pp. 287-293
- Rodman, J.H.¹ Furman, W.L.² Sunderland, M.³ Rivera, G.⁴ Evans, W.E.⁵

12
- 0011720863
- Limited sampling model for EO9, a novel indoloquinone cytotoxic drug
- 12. Schellens JH, Stoter G, Verweij J. Limited sampling model for EO9, a novel indoloquinone cytotoxic drug. Ann Oncol 1994, S5, 170.
- (1994) Ann Oncol , vol.S5 , pp. 170
- Schellens, J.H.¹ Stoter, G.² Verweij, J.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.